Overview of clinical trials with glycoprotein IIb-IIIa receptor antagonists in the prevention and management of coronary

Bibliography

• ANTIPLATELET TRIALISTS' COLLABORATION: Collaborative overview of randomised trials of antiplatelet ther-apy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. (1994) 308:81–106.
   PubMed Web of Science ®Google Scholar
• •This is a unique documentation of all antiplatelet trials until 1994.
   Google Scholar
• LEFKOVITS J, PLOW EF, TOPOL EJ: Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. NewEngl. J. Med. (1995) 332:1553–1559.
   PubMed Web of Science ®Google Scholar
• •Excellent overview on the pathophysiology of platelet func-tion and the integrin receptors.
   Google Scholar
• COLLER BS, PEERSCHKE El, SCUDDER LE, SULLIVAN CA: Amurine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoprotein IIb and/or Ma. J. Clin. Invest. (1983) 72:325–338.
   PubMed Web of Science ®Google Scholar
• COLLER BS, FOLTS JD, SCUDDER LE, SMITH SR: Anti-thrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experi-mental animal model. Blood (1986) 68:783–786.
   PubMed Web of Science ®Google Scholar
• THE EPIC INVESTIGATORS: Use of a monoclonal anti-body directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. New Engl. J. Med. (1994) 330:956–961.
   PubMed Web of Science ®Google Scholar
• •EPIC is a landmark study in GP IIb-IIIa development, since it was the first major clinical GP IIb-IIIa antagonist trial to dem-onstrate a clinical benefit of a new therapeutic approach in antiplatelet therapy.
   Google Scholar
• THE CAPTURE INVESTIGATORS: Randomised placebo-controlled trial of abciximab before and during coro-nary intervention in refractory unstable angina: the CAPTURE Study. Lancet (1997) 349:1429–1435.
   PubMed Web of Science ®Google Scholar
• THE EPILOG INVESTIGATORS: Platelet glycoproteinIIb/IIIa receptor blockade and low-dose heparin dur-ing percutaneous coronary revascularization. The EPI-LOG Investigators. NewEngl. J. Med. (1997) 336:1689–1696.
   PubMed Web of Science ®Google Scholar
• THE IMPACT-II INVESTIGATORS: Randomised placebo-controlled trial of effect of eptifibatide on complica-tions of percutaneous coronary intervention: IMPACT-II. Lancet (1997) 349:1422–1428.
   PubMed Web of Science ®Google Scholar
• HARRINGTON RA: Design and methodology of the PUR-SUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Am. J. Cardiol (1997) 80:34B-38B (1997).
   Google Scholar
• PARAGON INVESTIGATORS (MOLITERNO DJ): Oral pres-entation 69th Scientific Sessions of the American Heart Association, New Orleans, USA, November 10–13 (1996) [Abstract]. Circulation (1996) 94(Suppl. I) :553.
   Google Scholar
• PARAChute to the PARA Trials. Duke Clinical Research Insti-tute (1996).
   Google Scholar
• MOLITERNO DJ, HARRINGTON RA, CALIFF RM et al. Ran-domized, placebo-controlled study of lamifiban with thrombolytic therapy for the treatment of acute myo-cardial infarction: rationale and design for the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARA-DIGM). J. Thromb. Thrombol. (1995) 2:165–169.
   PubMedGoogle Scholar
• THE RESTORE INVESTIGATORS: Effects of platelet glyco-protein Ilb/Illa blockade with tirofiban on adverse car-diac events in patients with unstable angina or acute myocardial infarction undergoing coronary angio-plasty. Circulation (1997) 96:1445–1453.
   PubMed Web of Science ®Google Scholar
• WHITE H: Oral presentation. 46th Scientific Sessions of the American College of Cardiology. Anaheim, USA, 16–19 March (1997).
   Google Scholar
• THÉROUX P: Oral presentation. 46th Scientific Sessions of the American College of Cardiology. Anaheim, USA, 16–19 March (1997).
   Google Scholar
• PHILLIPS DR, TENG W, ARFSTEN A et al.: Effect of Ca2+ on GP Ilb-Illa interactions with integrilin - Enhanced GP Ilb-Illa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation (1997) 96:1488–1494.
   PubMed Web of Science ®Google Scholar
• •Describes the important influence of reduced Ca2+ concen-trations on integrilin binding. Chelation of Ca2+ by EDTA and citrate caused a similar degree of enhancement of the inhibi-tory activity of integrilin, thus overestimating its GP IIa-IIIb receptor blocking potency in blood samples collected with citrate.
   Google Scholar
• TCHENG JE, THEL MC, JENNINGS L et al.: Platelet glyco-protein Ilb/Illa receptor blockage with high-dose in-tegrilinTm in coronary intervention. Results of the PRIDE study. Eur. Hear. J. (1997) 18(Abstract Suppl.):624.
   Google Scholar
• TOPOL EJ, CALIFF RM, WEISMAN HF et al.: Randomised trial of coronary intervention with antibody against platelet Ilb/Illa integrin for reduction of clinical res-tenosis: results at six months. Lancet (1994) 343:881–886.
   PubMed Web of Science ®Google Scholar
• TOPOL EJ, FERGUSON JJ, WEISMAN HF et al.: Long-term protection from myocardial ischemic events in a ran-domized trial of brief integrin 133 blockade with percu-taneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet Ilb/Illa Inhibition for Pre-vention of Ischemic Complication. JAMA (1997) 278:479–484.
   Google Scholar
• •On long-term (up to 3 years) follow-up of the EPIC study, the sustained benefit of the initial GP IIb-IIIa blockade by abcixi-mab was found.
   Google Scholar
• AGUIRRE FV, TOPOL EJ, FERGUSON JJ et al.: Bleedingcomplications with the chimeric antibody to platelet glycoprotein Ilb/Illa integrin in patients undergoing percutaneous coronary intervention. Circulation (1995) 91:2882–2890.
   PubMed Web of Science ®Google Scholar
• TCHENG JE: Impact of eptifibatide on early ischemicevents in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Ag-gregation and Coronary Thrombosis. Am. J. Cardiol. (1997) 80:21B–28B.
   Google Scholar
• KLEIMAN NS: Primary and secondary safety endpointsfrom IMPACT II. Integrilin to Minimize Platelet Aggre-gation and Coronary Thrombosis. Am. J. Cardiol. (1997) 80:29B–33B.
   Google Scholar
• ALEXANDER JH, NEWBY LK, MOLITERNO DJ et al.: Rela-tionship of outcomes to treatment in patients undergo-ing PTCA: analysis of PARAGON A [abstract]. J. Am. Coll. Cardiol (1997) 29(Suppl. A):409A.
   Google Scholar
• HARRINGTON RA, NEWBY LK, MOLITERNO DJ et al.: Com-bining Ilb/Illa inhibition and heparin for acute coro-nary syndromes: evidence of a gradient for bleeding hazard from the PARAGON randomized factorially de-signed trial [abstract]. J. Am. Coll. Cardiol. (1997) 29(Suppl. A) :410A.
   Google Scholar
• LEFKOVITS J, BLANKENSHIP JC, ANDERSON KM et al.: In-creased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evi-dence from the EPIC trial. J. Am. Coll. Cardiol. (1996) 28:849–855.
   PubMed Web of Science ®Google Scholar
• LINCOFF AM, CALIFF RM, ANDERSON KM et al.: Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein Hb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J. Am. Coll. Cardiol (1997) 30:149–156.
   PubMed Web of Science ®Google Scholar
• LEFKOVITS J, IVANHOE RJ, CALIFF RM et al.: Effects of platelet glycoprotein Ilb/Illa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous translumi-nal coronary angioplasty for acute myocardial infarc-tion. Am. J. Cardiol. (1996) 77:1045–1051.
   PubMed Web of Science ®Google Scholar
• BOEHRER JD, KEREIAKES DJ, NAVETTA Fl et al.: Effects of profound platelet inhibition with c7E3 before coro-nary angioplasty on complications of coronary bypass surgery. Am. J. Cardiol. (1994) 74:1166–1170.
   PubMed Web of Science ®Google Scholar
• MOLITERNO DJ, CALIFF RM, AGUIRRE FV et al.: Effect of platelet glycoprotein Ilb/Illa integrin blockade on acti-vated clotting time during percutaneous coronary an-gioplasty or directional atherectomy (the EPIC trial). Am. J. Cardiol. (1995) 75:559–562.
   PubMed Web of Science ®Google Scholar
• LINCOFF AM, TCHENG JE, CALIFF RM et al.: Standard ver-sus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein Ilb/Illa receptor antibody fragment abciximab (c7E3 Fab) during percu-taneous coronary revascularization. PROLOG Investi-gators. Am. J. Cardiol (1997) 79:286–291.
   PubMed Web of Science ®Google Scholar
• FERGUSON JJ: EPILOG and CAPTURE trials halted be-cause of positive interim results. Circulation (1996) 93:637.
   PubMed Web of Science ®Google Scholar
• COLLER BS, ANDERSON, WEISMAN HF: New antiplatelet agents: platelet GP Ilb/Illa antagonists. Thromb. Haemo-stas. (1995) 74:302–308.
   PubMed Web of Science ®Google Scholar
• COLLER BS, SCUDDER LE, BERGER HJ, IULIUCCI JD: Inhi-bition of human platelet function in vivo with a mono-clonal antibody - with observations on the newly dead as experimental subjects. Ann. Intern. Med. (1988) 109:635–638.
   PubMed Web of Science ®Google Scholar
• •Describes the first human application of a GP IIb-IIIa blocker.
   Google Scholar
• GOLD HK, GIMPLE LW, YASUDA T et al.: Pharmacodynamic study of F(a102 fragments of murine mono-clonal antibody 7E3 directed against human platelet glycoprotein Ilb/IIIa in patients with unstable angina pectoris. J. Clin. Invest. (1990) 86:651–659.
   PubMed Web of Science ®Google Scholar
• SIMOONS ML, DE BOER MJ, VAN DEN BRAND MJBM et al.: Randomized trial of a GP Ilb/IIIa platelet receptor blocker in refractory unstable angina. European Coop-erative Study Group. Circulation (1994) 89:596–603.
   Google Scholar
• COLLER BS: Blockade of platelet GP Ilb/IIIa receptors as an antithrombotic strategy. Circulation (1995) 92:2373–2380.
   PubMed Web of Science ®Google Scholar
• •An concise and outstanding report on platelet pathophysiol-ogy and the development of the 7E3 antibody, for everyone interested in the history of abciximab.
   Google Scholar
• SCARBOROUGH RM, ROSE JW, HSU MA et al: Barbourin: aGP lb-IIIa specific integrin antagonist from the venom of Sistrurus m. barbouri. J. Biol. Chem. (1991) 266:9359–9362.
   PubMed Web of Science ®Google Scholar
• TCHENG JE, HARRINGTON RA, KOTTKE-MARCHANT K et al.: Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein lib-IIIa blocker integrilin in elective coronary interven-tion. Circulation (1995) 91:2151–2157.
   Google Scholar
• HARRINGTON RA, KLEIMAN NS, KOTTKE-MARCHANT K et al.: Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein Ilb/IIIa inhibitor during percutaneous coronary inter-vention. Am. J. Cardiol. (1995) 76:1222–1227.
   Google Scholar
• SCHULMAN SP, GOLDSCHMIDT-CLERMONT PJ, TOPOL EJet al.: Effects of integrelin, a platelet glycoprotein Ilb/IIIa receptor antagonist, in unstable angina - a ran-domized multicenter trial. Circulation (1996) 94:2083–2089.
   Google Scholar
• RODEN DM: Cardiovascular and renal advisory panel of the US Food and Drug Administration considers four drugs. Circulation (1997) 95:2335–2337.
   Web of Science ®Google Scholar
• PHILLIPS DR, SCARBOROUGH RM: Clinical pharmacol-ogy of eptifibatide. Am. J. Cardiol. 80\(Suppl. 40:11–20.
   Google Scholar
• TOPOL EJ: Results of PURSUIT. Oral presentation. Xle Congress of the European Society of Cardiology. Stockholm, Sweden 24–28 August (1997).
   Google Scholar
• PYTELA R, PIERSCHBACHER MD, GINSBERG MH et al.:Platelet membrane glycoprotein lib-IIIa: member of a family Arg-Gly-Asp specific adhesion receptors. Science (1986) 231:1559–1562.
   PubMed Web of Science ®Google Scholar
• PEERLINCK K, DE LEPELEIRE I, GOLDBERG M et al.: MK-383 (L-700,462), a selective nonpeptide platelet glyco-protein Ilb/IIIa antagonist, is active in man. Circulation (1993) 88\(Part 0:1512–1517.
   Google Scholar
• KEREIAKES DJ, KLEIMAN NS, AMBROSE J et al.: Random-ized, double-blind, placebo-controlled, dose-ranging study of tirofiban (MK-383) platelet Ilb/IIIa blockade in high risk patients undergoing coronary angioplasty. J. Am. Coll Cardiol (1996) 27:536–542.
   PubMed Web of Science ®Google Scholar
• THÉROUX P, KOUZ S, ROY L, KNUDTSON ML et al.: Plate-let membrane receptor glycoprotein Ilb/IIIa antago-nism in unstable angina - the Canadian lamifiban study. Circulation (1996) 94:899–905.
   PubMed Web of Science ®Google Scholar
• KLEIMAN NS, OHMAN EM, CALIFF RM et al. Profound in-hibition of platelet aggregation with monoclonal anti-body 7E3Fab after thrombolytic therapy. Results of the thrombolysis and angioplasty in myocardial infarction (TAMI-8) parallel study. J. Am. Coll. Cardiol. (1993) 22 :381–389.
   Google Scholar
• BERNADI MM, CALIFF RM, KLEIMAN N et al.: Lack of use-fulness of prolonged bleeding times in predicting hem-orrhagic events in patients receiving the 7E3 glycoprotein Ilb/IIIa platelet antibody. Am. J. Cardiol. (1993) 72:1121–1125.
   PubMed Web of Science ®Google Scholar
• GOLD HK, CIGARROA JE, FERRELL MA, COLLEN DJ, LEIN-BACH RC: Enhanced endogenous coronary thromboly-sis during acute myocardial infarction following selective platelet receptor blockade with ReoPro [ab-stract]. Circulation (1996) 94(Suppl.
   Google Scholar
• BRENER SJ, BARR LA, BURCHENAL J et al.: A randomized, placebo-controlled trial of abciximab with primary an-gioplasty for acute MI. The RAPPORT trial. Circulation (1997) 96 (Suppl.) . To be presented at 70th Scientific Sessions of the American Heart Association. Orlando, USA 9–12 No-vember (1997).
   Google Scholar
• OHMAN EM, KLEIMAN NS, GACIOCH G et al.: Combinedaccelerated tissue-plasminogen activator and platelet glycoprotein Ilb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. Circulation (1997) 95:846–854.
   PubMed Web of Science ®Google Scholar
• CATELLA-LAWSON F, FITZGERALD GA: Confusion in reperfusion - problems in the clinical development of antithrombotic drugs. Circulation (1997) 95:793–795.
   PubMed Web of Science ®Google Scholar
• MOLITERNO DJ, HARRINGTON RA, KRUCOFF MW et al.: More complete and stable reperfusion with platelet Ilb/IIIa antagonism plus thrombolysis for AMI: the paradigm trial. Circulation (1996) 94 (Suppl. D:1–553.
   Google Scholar
• WILLERSON JT: Inhibitors of platelet glycoprotein Ilb/IIIa receptors - will they be useful when given chronically? Circulation (1996) 94:866–868.
   PubMedGoogle Scholar
• WILLER TH, WEISENBERGER H, BRICKL R et al: Profound and sustained inhibition of platelet aggregation by fra-dafiban, a nonpeptide platelet glycoprotein Ilb/IIIa an-tagonist, and its orally active prodrug, lefradafiban, in man. Circulation (1997) 96:1130–1138.
   PubMed Web of Science ®Google Scholar
• VAN DEN BRAND MJBM, BAARDMAN T, SURYAPRANATA H et al.: Initial experience with BIBU 104XX; a new, oral glycoprotein Ilb-IIIa receptor blocker [abstract]. Eur. Heart J. (1997) 18(Suppl.):18.
   Google Scholar
• VAN DEN BRAND MJBM, BAARDMAN T, SURYAPRANATA H et al.: BIBU 104xx: a new, oral glycoprotein Ilb-IIIa re-ceptor blocker, initial experience. Circulation (1997) 96 (Suppl.). To be presented at 70th Scientific Sessions of the American Heart Association. Orlando, USA 9–12 November (1997).
   Google Scholar
• CANNON CP, KENNETH A, MITCHELL J, MCCABE CH, BRAUNWALD E: P-selectin in patients post acute coro-nary syndromes treated with sibrafiban, an oral Ilb/IIIa antagonist: results from TIMI 12. Circulation (1997) 96 (Suppl.). To be presented at 70th Scientific Sessions of the American Heart Association, Orlando, USA 9–12 November (1997).
   Google Scholar
• CANNON CP, NOVOTNY WF, MCCABE CH et al.: Evalua-tion of the oral glycoprotein Ilb/IIIa antagonist Ro 48–3657 in patients post acute coronary syndromes: pri-mary result of the TIMI 12 trial [abstract]. Circulation (1996) 94 (Suppl.):1–552.
   Google Scholar
• KEREIAKES DJ, FERGUSON JJ, MASUD AZ et al.: Sustained platelet GP Ilb-IIIa blockade with oral xemilofiban: fi-nal results of the ORBIT trial. Circulation (1997) 96 (Suppl.). To be presented at 70th Scientific Sessions of the American Heart Association, Orlando, USA, 9–12 November (1997).
   Google Scholar
• KEREIAKES DJ, RUNYON JP, KLEIMAN NS et al.: Differen-tial dose-response to oral xemilofiban after antecedent intravenous abciximab - administration for complex coronary intervention. Circulation (1996) 94:906–910.
   PubMed Web of Science ®Google Scholar
• SIMPFENDORFER C, KOTTKE-MARCHANT K, TOPOL EJ: First experience with chronic platelet GP Ilb/IIIa recep-tor blockade: a pilot study of xemilofiban an orally ac-tive antagonist in unstable angina patients eligible for PTCA [abstract]. J. Am. Coll. Cardiol. (1996) 27(Suppl. A):242A.
   Google Scholar
• KEREIAKES DJ, KLEIMAN N, FERGUSON JJ et al.: Sustained platelet glycoprotein Ilb/IIIa blockade with oral xemi-lofiban in 170 patients after coronary stent deploy-ment. Circulation (1997) 96:1117–1121.
   PubMed Web of Science ®Google Scholar
• MOUSA SA, BOZARTH J, FORSYTHE X et al: Discovery of anovel non-peptide antiplatelet GPIlb/IIIa receptor antagonist, DMP754: a receptor binding affinity and specificity [abstract]. Circulation (1996) 94 (Suppl.):1–513.
   Google Scholar
• MOUSA SA, BOZARTH J, FORSYTHE X et al.: Intravenous and oral antiplatelet/antithrombotic efficacy and specificity of XR3000, a novel non-peptide platelet GPIIb/IIIa antagonist [abstract]. Circulation (1996) 94 (Suppl.):I–99.
   Google Scholar
• FEUERSTEIN G, WONG A, NICHOLS A et al.: 5B214857: a novel non-peptide orally active potent and selective platelet GPIlb/IIIa receptor antagonist: in vitro and in vivo pharmacology [abstract]. Circulation (1996) 94 (Suppl.)1–513.
   Google Scholar
• TOPOL EJ: Targeted approaches to thrombus inhibition - an end to the shotgun approach. Clin. Cardiol. (1997) 20(Suppl.
   Google Scholar